KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Receivables: 2009-2025

Historic Change in Receivables for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $59.9 million.

  • Vertex Pharmaceuticals' Change in Receivables rose 15.64% to $59.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.9 million, marking a year-over-year increase of 17.00%. This contributed to the annual value of $99.3 million for FY2024, which is 18.07% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Change in Receivables stood at $59.9 million, which was up 225.54% from $18.4 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Change in Receivables ranged from a high of $251.6 million in Q1 2024 and a low of -$135.1 million during Q2 2024.
  • Its 3-year average for Change in Receivables is $39.2 million, with a median of $18.4 million in 2025.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Change in Receivables soared by 1,531.11% in 2021 and then crashed by 4,758.62% in 2024.
  • Vertex Pharmaceuticals' Change in Receivables (Quarterly) stood at $43.5 million in 2021, then slumped by 123.45% to -$10.2 million in 2022, then tumbled by 50.98% to -$15.4 million in 2023, then tumbled by 348.05% to -$69.0 million in 2024, then grew by 15.64% to $59.9 million in 2025.
  • Its Change in Receivables stands at $59.9 million for Q3 2025, versus $18.4 million for Q2 2025 and $169.6 million for Q1 2025.